GAITHERSBURG, Md., Feb. 13 /PRNewswire/ -- Lentigen Corporation today announced the company is moving its corporate headquarters and manufacturing facilities from the University of Maryland Baltimore County TechCenter to a new 26,000 square-foot facility in Gaithersburg.
Located along Maryland's I-270 technology corridor, the expanded facility will accommodate Lentigen's future growth needs as a leading developer and manufacturer of lentiviral vectors and proteins for a wide range of therapeutic and research applications. Two self-contained suites will allow simultaneous multi-product manufacture in compliance with FDA-regulated current good manufacturing practices and EMEA regulatory standards.
"We are very pleased to have found a facility that will meet our expansion requirements for both research-grade and clinical-grade operations," said Tim Ravenscroft, Lentigen's chief executive officer. "Located in the heart of Maryland's technology corridor, we will be well situated to attract talented individuals to our growing organization and to meet the increasing needs of our partners and customers."
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused
on the development of lentiviral vector technology for a wide range of
therapeutic, vaccine and research applications in biotechnology and
medicine. Lentiviral vectors are the most efficient vehicles for the
delivery of genes or gene silencing sequences stably into cells. Lentigen
is a highly collaborative company, co-developing lentiviral vector-based
products across a broad spectrum of bench to clinical applications.
Partnerships include The National Institutes of Health, The University of
Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further
information, visit http://www.lentigen.com/
Richard Lewis Communications, Inc.
|SOURCE Lentigen Corporation|
Copyright©2008 PR Newswire.
All rights reserved